🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
07/10/2016 15,03 15,03 14,66 14,74 -2,32% 2,46% 4.524
06/10/2016 15,00 15,09 14,80 15,09 +0,20% 1,93% 11.536
05/10/2016 15,30 15,30 15,00 15,06 +0,40% 1,96% 3.721
04/10/2016 15,13 15,21 15,00 15,00 -0,86% 1,39% 6.889
03/10/2016 15,35 15,40 15,06 15,13 -1,11% 2,21% 10.015
30/09/2016 15,10 15,30 15,04 15,30 +0,79% 1,72% 7.302
29/09/2016 15,10 15,20 15,04 15,18 -0,46% 1,06% 102.602
28/09/2016 15,25 15,25 15,05 15,25 +0,00% 1,31% 1.914
27/09/2016 15,25 15,25 14,87 15,25 +0,33% 2,49% 7.794
26/09/2016 15,38 15,38 15,11 15,20 +0,33% 1,76% 8.066
23/09/2016 15,11 15,30 15,10 15,15 +0,33% 1,32% 38.592
22/09/2016 15,30 15,30 15,05 15,10 -0,98% 1,63% 10.741
21/09/2016 15,17 15,25 14,87 15,25 +1,80% 2,50% 8.107
20/09/2016 15,00 15,00 14,71 14,98 -0,13% 1,93% 12.565
19/09/2016 15,15 15,24 14,72 15,00 -0,99% 3,43% 40.916
16/09/2016 14,72 15,35 14,65 15,15 +2,92% 4,76% 14.501
15/09/2016 15,00 15,00 14,62 14,72 -2,84% 2,53% 19.039
14/09/2016 15,00 15,15 14,90 15,15 +0,33% 1,67% 6.513
13/09/2016 14,90 15,30 14,80 15,10 +5,08% 3,36% 9.174
12/09/2016 14,45 14,45 14,00 14,37 -0,55% 3,11% 7.054
09/09/2016 14,25 14,49 14,25 14,45 +0,21% 1,68% 5.687
08/09/2016 14,26 14,47 14,20 14,42 +1,34% 1,89% 4.955
07/09/2016 14,40 14,40 14,00 14,23 +0,35% 2,78% 5.738
06/09/2016 14,05 14,30 14,05 14,18 +1,14% 1,78% 983
05/09/2016 14,50 14,84 13,75 14,02 -1,41% 7,52% 58.853
02/09/2016 14,20 14,25 13,95 14,22 +1,94% 2,11% 10.010
01/09/2016 14,00 14,16 13,87 13,95 +0,22% 2,07% 18.023
31/08/2016 14,00 14,00 13,78 13,92 +1,61% 1,57% 3.908
30/08/2016 14,19 14,20 13,70 13,70 -3,52% 3,52% 6.389
29/08/2016 13,72 14,20 13,71 14,20 +5,19% 3,57% 5.815